Pharmaceutical composition for treating brain disease, neuronal migration promoter, and use thereof

A neuraminidase inhibitor-based pharmaceutical composition addresses the challenges of neuron migration and regeneration in brain diseases by inhibiting Neu1 and Neu4, promoting neuron migration and regeneration to injured sites, thereby improving brain function.

JP2024164305APending Publication Date: 2024-11-26NAGOYA CITY UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024153540
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-12
Filing Date
2024-09-05
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing methods for regenerating nerve cells in brain diseases, such as cerebral infarction, face challenges including the risk of tumor formation and invasive surgical procedures, and there is a need for safer and more effective techniques to promote neuron migration and regeneration.

Method used

A pharmaceutical composition containing a neuraminidase inhibitor, specifically targeting Neu1 and Neu4, is administered to promote neuron migration by inhibiting the cleavage of polysialic acid, thereby facilitating the migration of neurons to injured sites in the brain.

Benefits of technology

The neuraminidase inhibitor effectively promotes neuron migration and regeneration, enhancing the recovery of brain function by increasing the number of neurons reaching the injury site and allowing them to mature, thus improving motor functions in brain diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164305000001_ABST
    Figure 2024164305000001_ABST
Patent Text Reader

Abstract

To provide a technology that can promote neuronal migration.SOLUTION: A pharmaceutical composition for treating brain disease includes a neuraminidase inhibiting substance. A neuronal migration promoter includes a neuraminidase inhibiting substance. A method for promoting neuronal migration includes a step for bringing a neuraminidase inhibiting substance into contact with neurons.SELECTED DRAWING: Figure 3
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to a pharmaceutical composition and a neuronal migration promoter for the treatment of brain diseases. This application is based on Japanese Patent Application No. 2022-144880 filed on September 12, 2022, the contents of which are incorporated herein by reference. [Background technology]

[0002] In order to fundamentally treat brain diseases such as cerebral infarction, a technology is required to regenerate lost nerve cells and restore brain function. As such a technology, for example, a method of transplanting cells induced from iPS cells is known, as shown in Patent Document 1. In addition, a method of promoting regeneration by inducing nerve cells produced from endogenous neural stem cells to the damaged site is known, as shown in Patent Document 2. In Patent Document 2, a sponge-like material to which N-cadherin or the like is fixed or coated is used to promote the migration of neurons (nerve cells) in damaged tissue occurring on the surface layer of the brain. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] International Publication No. 2013 / 069661 [Patent Document 2] JP 2020-018796 A Summary of the Invention [Problem to be solved by the invention]

[0004] When nerve cells produced from iPS cells, as described in Patent Document 1, are transplanted to an injured site, there is a concern that the transplanted cells may form a tumor in the brain, as well as invasively invading the brain. In addition, in order to guide nerve cells produced from endogenous neural stem cells to an injured site, a technique of transplanting an artificial scaffold such as a biomaterial, as described in Patent Document 2, involves invasiveness due to brain surgery. For this reason, there is room for improvement in clinical use as regenerative medicine for brain diseases. For this reason, there has been a demand for other techniques that can promote the migration and regeneration of neurons. Therefore, the present inventors have invented other techniques that can promote the migration and regeneration of neurons by conducting intensive research. [Means for solving the problem]

[0005] The present invention can be realized in the following forms.

[0006] (1) According to one embodiment of the present invention, there is provided a pharmaceutical composition for treating brain diseases. The pharmaceutical composition contains a neuraminidase inhibitor. According to this embodiment of the pharmaceutical composition, the inclusion of a neuraminidase inhibitor can promote neuronal migration, and therefore the pharmaceutical composition can be used for treating brain diseases.

[0007] (2) In the pharmaceutical composition according to (1) above, the neuraminidase inhibitor may inhibit at least one of Neu1 and Neu4. According to this form of the pharmaceutical composition, the neuraminidase inhibitor inhibits at least one of Neu1 and Neu4, and thus it is possible to effectively promote neuronal migration.

[0008] (3) In the pharmaceutical composition according to (1) or (2) above, administration may be started within 10 days after the onset of the brain disease and administered daily. According to this form of pharmaceutical composition, administration is started within 10 days after the onset of the brain disease and administered daily, so that migration of neurons can be effectively promoted.

[0009] (4) The pharmaceutical composition according to (3) above may be administered for 10 days or more. This form of pharmaceutical composition is administered daily for a period of 10 days or more, and therefore can more effectively promote neuronal migration.

[0010] (5) The pharmaceutical composition according to any one of (1) to (4) above may be administered in the form of an injection. This form of pharmaceutical composition is administered in the form of an injection, so that invasion can be suppressed.

[0011] (6) According to another aspect of the present invention, there is provided a neuronal migration promoter. This neuronal migration promoter contains a neuraminidase inhibitor. According to this aspect of the neuronal migration promoter, the inclusion of a neuraminidase inhibitor can promote neuronal migration.

[0012] (7) In the neuronal migration promoter described in (6) above, the neuraminidase inhibitor may inhibit at least one of Neu1 and Neu4. According to this form of neuronal migration promoter, the neuraminidase inhibitor inhibits at least one of Neu1 and Neu4, and thus neuronal migration can be effectively promoted.

[0013] (8) According to another aspect of the present invention, there is provided a method for treating a brain disease. This method includes a step of administering a neuraminidase inhibitor to a patient with a brain disease. According to this aspect of the method, since it includes a step of administering a neuraminidase inhibitor to a patient with a brain disease, it is possible to promote migration of neurons, and as a result, it can be used for treating the brain disease.

[0014] (9) According to another aspect of the present invention, there is provided a method for promoting neuronal migration, comprising the step of contacting a neuraminidase inhibitor with the neuron. According to the method of this aspect, since it comprises the step of contacting a neuraminidase inhibitor with the neuron, it is possible to promote neuronal migration.

[0015] (10) According to another aspect of the present invention, there is provided the use of a neuraminidase inhibitor for treating a brain disease.

[0016] The present disclosure can be realized in various forms, for example, as a neuron migration promoter, a neuron migration promotion kit, a kit including a pharmaceutical composition, a method for producing a neuron migration promoter, a method for producing a pharmaceutical composition, a method for promoting the migration of new neurons, a method for assisting the regeneration of damaged brain tissue, a method for treating brain diseases, use as a neuron migration promoter, use for promoting neuron migration, use of a neuraminidase inhibitor for producing a neuron migration promoter, use of a neuraminidase inhibitor for producing a brain disease treatment drug, etc. [Brief description of the drawings]

[0017] [Figure 1] Schematic diagram showing how neuraminidase cleaves PSA-NCAM. [Diagram 2] A flow chart showing a method for treating brain disorders. [Diagram 3] FIG. 2 is a flow diagram showing a method for promoting neuronal migration. [Figure 4] FIG. 1 is an explanatory diagram showing SBF-SEM image data in Experiment 1. [Diagram 5] FIG. 1 is an explanatory diagram illustrating the rate of cell adhesion as a result of Experiment 1. [Figure 6] FIG. 13 is an explanatory diagram showing a microscopic image in Experiment 2. [Figure 7] An explanatory diagram showing the fluorescence intensity of PSA-NCAM in Experiment 2. [Figure 8] FIG. 13 is an explanatory diagram showing a microscopic image in Experiment 3. [Figure 9] An explanatory diagram illustrating the rate of cell adhesion as a result of Experiment 3. [Figure 10] FIG. 1 is an explanatory diagram showing the expression levels of Neu1 to 4 in normal and injured brains. [Figure 11] FIG. 1 is an explanatory diagram showing a comparison of the expression levels of Neu1 to Neu4 in injured brains. [Figure 12] FIG. 1 is a schematic diagram showing the sites of brain damage in mice in Experiment 5. [Figure 13] FIG. 13 is an explanatory diagram showing a microscope image in Experiment 5. [Figure 14] An explanatory diagram showing signal intensities in Experiment 5. [Figure 15] FIG. 13 is an explanatory diagram showing a microscopic image from Experiment 6. [Figure 16] An explanatory diagram showing signal intensities in Experiment 6. [Figure 17] FIG. 13 is an explanatory diagram showing a microscopic image from Experiment 7. [Figure 18] FIG. 13 is an explanatory diagram showing the number of double-positive cells in Experiment 7. [Figure 19] FIG. 1 is an explanatory diagram showing the process of FFT. [Figure 20] An explanatory diagram showing the results of Experiment 8. [Figure 21] FIG. 1 is a schematic diagram showing the brain regions used for the quantification of sialic acid in Experiment 9. [Figure 22] FIG. 13 is an explanatory diagram showing the quantitative results of sialic acid in Experiment 9. [Diagram 23] An explanatory diagram showing an overview of Experiment 10. [Figure 24] FIG. 13 is an explanatory diagram showing a representative example of a microscope image in Experiment 10. [Diagram 25] FIG. 13 is an explanatory diagram showing PSA signal intensity in experiment 10. [Figure 26] FIG. 13 is an explanatory diagram showing the results of time-lapse imaging in Experiment 10. [Figure 27] An explanatory diagram showing the migration speed of neurons in Experiment 10. [Figure 28] FIG. 13 is an explanatory diagram showing a representative example of a microscopic image in Experiment 11. [Figure 29] An explanatory diagram showing the number of double positive cells in Experiment 11. [Diagram 30] An explanatory diagram showing the results of Experiment 12. [Diagram 31] FIG. 13 is an explanatory diagram showing a representative example of a microscopic image in Experiment 13. [Diagram 32] An explanatory diagram showing the fluorescence intensity of PSA-NCAM in Experiment 13. [Diagram 33] An explanatory diagram showing the distance from the injury site in Experiment 13. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] According to one embodiment of the present disclosure, there is provided a neuronal migration promoter, the neuronal migration promoter comprising a neuraminidase inhibitor.

[0019] Neurons include, but are not limited to, newborn neurons produced from endogenous neural stem cells. Other neurons include, but are not limited to, neurons induced to differentiate from pluripotent stem cells such as iPS cells (induced pluripotent stem cells) and ES cells (embryonic stem cells). Subjects include, but are not limited to, mammals including humans, and non-human mammals such as monkeys, mice, rats, rabbits, dogs, cats, sheep, goats, horses, cows, and pigs.

[0020] Neuraminidase is an enzyme that cleaves polysialic acid (PSA). There are two types of neuraminidase: exo-type (EC 3.2.1.18) and endo-type (EC 3.2.1.129). Neuraminidase is also called sialidase. There are four subtypes of mammalian neuraminidase: Neu1, Neu2, Neu3, and Neu4. The reference sequence RNA for human Neu1 is NM_000434. The reference sequence RNA for human Neu2 is NM_005383. The reference sequence RNA for human Neu3 is NM_006656. The reference sequence RNA for human Neu4 is NM_080741.

[0021] The neuraminidase inhibitor may include a substance that inhibits the activity of neuraminidase and a substance that inhibits the expression of neuraminidase. The neuraminidase inhibitor is not particularly limited, but may include, for example, 2,3-dehydro-2-deoxy-N-acetylneuraminic acid (DANA), zanamivir, oseltamivir, peramivir, laninamivir, siRNA and miRNA that inhibit the expression of neuraminidase. As shown in the examples described below, the neuraminidase inhibitor preferably inhibits at least one of Neu1 and Neu4. For this reason, it is preferable to include a human Neu1 specific inhibitor (e.g., Magesh et al., 2008) or a Neu4 specific inhibitor. Among clinical drugs, zanamivir is preferable from the viewpoint that an inhibitory effect on at least Neu2, Neu3, and Neu4 of human neuraminidase has been reported.

[0022] The mechanism by which inclusion of a neuraminidase inhibitor promotes neuronal migration is not clear, but the following putative mechanism is hypothesized based on the results shown in the Examples described below.

[0023] FIG. 1 is an explanatory diagram showing a schematic diagram of neuraminidase cleaving PSA-NCAM. Incidentally, NCAM (neural cell adhesion molecule) is a cell adhesion molecule. It is considered that polysialic acid creates an exclusive space due to its bulky structure. Here, the present inventors considered that, in the process in which nerve cells produced by neural stem cells present in the subventricular zone migrate to the injured area after brain injury, the phenomenon of cleavage of sugar-linked polysialic acid on the surface of nerve cells by neuraminidase occurs. It is assumed that cleavage of sugar-linked polysialic acid causes excessive cell adhesion between nerve cells, thereby inhibiting the migration of nerve cells. For this reason, the present inventors considered that the migration of nerve cells can be promoted by inhibiting the cleavage of sugar-linked polysialic acid with a neuraminidase inhibitor, thereby inhibiting excessive cell adhesion. In addition, it is expected that, as a result of enabling the migration of many nerve cells to the injured area, many immature nerve cells will reach the injured area and differentiate and mature into nerve cells. As a result, the regeneration of nerve cells is promoted, which may make it possible to restore brain and motor functions that have been impaired by brain diseases.

[0024] The neuronal migration promoter of the present embodiment may be used for the treatment or prevention of a disease or condition. The disease or condition may be, but is not limited to, hypoxic-ischemic encephalopathy, cerebral infarction, cerebral hemorrhage, cerebrovascular disease, central nervous system disease, Alzheimer's disease, cognitive impairment, trauma, etc. Therefore, according to another embodiment of the present disclosure, a pharmaceutical composition for the treatment of brain disease is provided. The pharmaceutical composition includes a neuraminidase inhibitor.

[0025] The neuronal migration promoter and pharmaceutical composition may contain a pharma- ceutically acceptable carrier. In this specification, the term "pharma-ceutically acceptable carrier" refers to an additive commonly used in the field of formulation technology. Examples of such carriers include, but are not limited to, solvents, excipients, fillers, emulsifiers, flow additive regulators, lubricants, human serum albumin, and the like. The solvent may be, for example, water or any other pharma- ceutically acceptable aqueous solution, or a pharma-ceutically acceptable organic solvent. Examples of aqueous solutions include, but are not limited to, physiological saline, isotonic solutions containing glucose or other adjuvants, phosphate buffer, sodium acetate buffer, and the like. Examples of adjuvants include, but are not limited to, D-sorbitol, D-mannose, D-mannitol, sodium chloride, and other low-concentration nonionic surfactants, polyoxyethylene sorbitan fatty acid esters, and the like.

[0026] Examples of excipients include, but are not limited to, sugars such as monosaccharides, disaccharides, cyclodextrins and polysaccharides, metal salts, citric acid, tartaric acid, glycine, polyethylene glycol, Pluronic®, kaolin, silicic acid, or combinations thereof. Examples of fillers include, but are not limited to, petrolatum, the above sugars and / or calcium phosphate, etc. Examples of emulsifiers include, but are not limited to, sorbitan fatty acid esters, glycerin fatty acid esters, sucrose fatty acid esters, propylene glycol fatty acid esters, etc. Examples of flow additive regulators and lubricants include, but are not limited to, silicates, talc, stearates, polyethylene glycols, etc. In addition to the above, if necessary, the composition may appropriately contain solubilizers, suspending agents, diluents, dispersing agents, surfactants, soothing agents, stabilizers, absorption promoters, bulking agents, moisturizing agents, humectants, adsorbents, flavorings, deodorants, disintegration inhibitors, coating agents, colorants, preservatives, antiseptics, antioxidants, fragrances, flavorings, sweeteners, buffers, isotonicity agents, and the like that are commonly used in medicines.

[0027] The dosage form of the neuron migration promoter according to this embodiment is not particularly limited, but is preferably a form that can be delivered to the target site in the brain of the subject without inactivating the properties. The dosage form of the neuron migration promoter is not particularly limited, but examples thereof include liquids, powders, granules, tablets, etc. The dosage form of the neuron migration promoter is preferably a liquid from the viewpoint of facilitating delivery to the target site in the brain of the subject. The liquid is not particularly limited, but examples thereof include injections such as injections and drips. The injection is not particularly limited, but is preferably an arterial injection or an intramuscular injection from the viewpoint of facilitating delivery of the neuron migration promoter to the target site. According to such a form, invasiveness can be suppressed. Furthermore, according to such a form, neuron migration can be easily promoted in the brain of the subject. Furthermore, compared to local transplantation of cells or scaffolding materials, etc., neuron migration can be promoted by a less invasive and safe technique. Furthermore, compared to local transplantation of cells or scaffolding materials, etc., nerve cells can be regenerated against injuries that cover a wide range in the brain. The neuronal migration promoter may be directly administered into the brain, or may be impregnated into a scaffold material or the like and then transplanted into the brain. The neuronal migration promoter may have sustained release properties, and may be in a form in which the neuraminidase inhibitor is sustainedly released over a period of several hours, several days, several weeks, or the like by remaining at a desired site in the subject's brain. The neuronal migration promoter may be formulated in appropriate combination with the above-mentioned stabilizers, pH regulators, excipients, and the like, or may be combined with a syringe or other device for administration to form a kit.

[0028] The administration timing and dosage of the neuronal migration promoter and pharmaceutical composition in this embodiment can be appropriately determined according to the subject, disease, or condition to be administered. The administration timing is not particularly limited, but for example, it is desirable to administer continuously for the period during which neuronal migration is desired to be promoted. For continuous administration, it is preferable to administer at least once every 3 days, more preferably at least once every 2 days, and even more preferably once a day, that is, every day. In addition, the start timing of administration is not particularly limited, but for example, it is preferable to be at the timing when neurons start to migrate or before neurons start to migrate. The start timing of administration is not particularly limited, but for example, from the viewpoint of effectively promoting neuronal migration, it is preferable to be before 20 days have passed since the onset of brain disease, more preferably before 15 days have passed, even more preferably before 12 days have passed, even more preferably before 10 days have passed, and particularly preferably before 8 days have passed. In addition, the timing of administration is not particularly limited, but from the viewpoint of effectively promoting neuronal migration, it is preferably 3 days or more after the onset of brain disease, more preferably 5 days or more, and even more preferably 7 days or more. The administration period is not particularly limited, but from the viewpoint of effectively promoting neuronal migration, it is preferably 5 days or more, more preferably 7 days or more, even more preferably 10 days or more, even more preferably 12 days or more, and especially preferably 14 days or more. It is preferable to start administration from 3 days to 10 days after the onset of brain disease and administer daily for 10 days or more, and more preferably to start administration from 5 days to 8 days after the onset of brain disease and administer for 14 days or more. For example, administration may be started 7 days after the onset of brain disease and administered for 14 days. The dosage varies depending on the severity of the brain disease, the sex, age, and weight of the patient, and may be, for example, 1 to 90 mg of neuraminidase inhibitor / kg body weight / day.

[0029] According to another embodiment of the present disclosure, a method for treating a brain disease is provided. FIG. 2 is a flow chart showing the method for treating a brain disease. This method includes a step (P110) of administering a neuraminidase inhibitor to a brain disease patient. This step may be performed according to the administration timing and dosage described above. The method for treating a brain disease may further include a step of determining the dosage of the neuraminidase inhibitor before the step of administering the neuraminidase inhibitor to the brain disease patient. In this step, the dosage may be determined according to, for example, the severity of the brain disease, or the sex, age, and weight of the patient. The method for treating a brain disease may further include a step of confirming the effect of the administration after the step of administering the neuraminidase inhibitor to the brain disease patient. In this step, the effect may be confirmed by, for example, a behavioral test.

[0030] According to another embodiment of the present disclosure, there is provided a method for promoting neuronal migration. FIG. 3 is a flow chart showing a method for promoting neuronal migration. The method includes a step (P210) of contacting a neuraminidase inhibitor with a neuron. The step of contacting a neuraminidase inhibitor with a neuron may be achieved by administering the neuraminidase inhibitor to a subject. This administration may be performed according to the administration timing and dosage described above. The step of contacting a neuraminidase inhibitor with a neuron may not include a medical procedure on a human. EXAMPLES

[0031] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following examples.

[0032] 1. Materials and Methods (1) Sample Wild-type (WT) male and female C57BL / 6J mice were purchased from Japan SLC Co., Ltd. (RRID:IMSR_JAX:000664). Dcx-GFP mice were obtained by the method described in Gong et al., Nature 425, p.917-925 (2003). Nestin-CreERT2; neuron-specific enolase (NSE)-diphtheria toxin fragment A (DTA) mice were obtained by the method described in Nat.Neurosci.11, 1153-61 (2008). Common marmosets (Callithrix jacchus) were used from a mating pair in a breeding animal colony. Tamoxifen was administered by the method described in Nat.Neurosci.11, 1153-61 (2008).

[0033] (2) Induction of cerebral cortical damage As the injured brain, damage to the cerebral cortex of mice was artificially induced. The cerebral cortex damage was induced by modifying the method for producing an ischemic brain injury model (photothrombosis) by light stimulation reported by Watson et al. (Watson et al., 1985) as shown below. Mice aged 8 to 12 weeks were anesthetized by administering oxygen / isoflurane mixed gas (97.5 / 2.5%) using an inhalation mask, and then placed on a heated bed at 37°C. The scalp was incised to expose the skull surface, and the bregma and target site were identified. An 8 mm diameter fiber optic cable connected to a light source for light irradiation (MSG6-1100S, Moritex Corporation) was stereotaxically fixed on the skull 1 mm anterior and 2.7 mm lateral to the bregma. Cerebral cortical ischemic injury was induced by activating the photosensitive rose bengal dye (30 mg / kg, 330000-1G, Sigma-Aldrich) in 0.9% NaCl solution. Rose bengal was injected intravenously. The skull was illuminated for 10 minutes at 533 nm and 150 mW using a MHAA-100W-100V (Moritex). For common marmosets, a modified method for producing an ischemic brain injury model by light stimulation (Photothrombosis) was used according to the description in PLoS One.8, e60037 (2013). Cerebral ischemia in common marmosets (3 months old) was induced by intravenous injection of rose bengal (30 mg / kg) under deep anesthesia and irradiation with green light (533 nm, metal halide lamp, PCS-MH357RC, Japan PI) for 5 to 10 minutes to induce intravascular thrombosis. All surgeries were performed under general anesthesia induced by intramuscular injection of medetomidine (0.04 mg / kg), midazolam (0.4 mg / kg) and butorphanol (0.4 mg / kg), maintained by isoflurane, and antagonized by atipamezole (0.15 mg / kg). The scalp was incised to expose the skull surface and washed to reveal the bregma and target site. A 12 mm diameter optical fiber cable connected to a light source for light irradiation (PLG-1-1000-3R-UX350, manufactured by Japan PI Corporation) was stereotaxically fixed on the skull 5 mm anterior to the skull and 6 mm lateral to the bregma.

[0034] (3) Serial block-face scanning electron microscope (SBF-SEM) Sample preparation, observation by serial block-face scanning electron microscopy (SBF-SEM), and analysis of acquired data were performed according to existing methods with minor modifications (Kaneko et al., 2018; Nguyen et al., 2016; Sawada et al., 2018; Thai et al., 2016). Adult wild-type mouse brains were perfusion-fixed in 0.1 M phosphate buffer (pH 7.4) containing 2.5% glutaraldehyde (GA) and 2% PFA at 4°C, and further fixed overnight at 4°C with the same fixative. Fixed RMS tissues or tissues adjacent to the brain lesion were treated in PBS containing 2% OsO4 and 1.5% potassium ferricyanide for 1 h at 4°C. The tissues were then treated in 1% thiocarbohydrazine at room temperature for 20 min, followed by treatment in 2% OsO4 aqueous solution at room temperature for 30 min, and then in lead aspartate aqueous solution at 65°C for 30 min. The RMS tissues were then dehydrated in a series of ethanol dilutions, treated with dehydrated acetone, and embedded in Durcupan resin containing Ketjen black powder at 95°C for 3 h for polymerization. SBF-SEM observations of RMS tissues in normal and injured brains were performed using Merlin and Sigma scanning electron microscopes (Carl Zeiss) equipped with a 3View in-chamber ultramicrotome system (Gatan). Sequential images were created with a width of 40.96 × 40.96 μm (5.0 nm / pixel), a depth of more than 80 μm, and 80 nm steps. Sequential images were processed with FIJI. Segmentation of cell membranes, nuclei, and centrosomes was performed using Microscopy Image Browser (Belevich et al., 2016). Manual segmentation was performed on all slices. Three-dimensional reconstruction of migrating newborn neurons and their intracellular organelles was performed using Amira software (Maxnet) as previously described (Kaneko et al., 2018; Sawada et al., 2018; Matsumoto et al., 2019).

[0035] (4) Immunohistochemistry and image acquisition Immunohistochemistry on mouse brain sections was performed according to published methods (Ota et al., 2014; Sawada et al., 2018). More specifically, mouse adult brains were perfusion-fixed with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) and further fixed overnight at 4°C using the same fixative. Free-floating coronal and sagittal sections of 50 μm thickness were made using a vibratome (VT-1200S, Leica) and incubated for 30 min at room temperature in PBS containing 10% normal donkey serum (NDS) and 0.2% Triton X-100 as a blocking solution. These sections were incubated with primary antibodies in blocking solution overnight at 4°C, and then incubated with AlexaFluor488 / 568 / 647-labeled secondary antibodies (1:1,000, Invitrogen) in blocking solution for 2 h at room temperature. The following antibodies were used as primary antibodies. Rabbit anti-doublecortin (Dcx) (1:1,000, 4604S, Cell Signaling Technology; RRID:AB_10693771), rabbit anti-DsRed (1:1,000, 632496, Clontech; RRID:AB_10013483), mouse IgM anti-polysialylated neural cell adhesion molecule (PSA-NCAM) (1:1000, provided by Professor Emeritus Ishi Ryunori, Tokyo Medical University) (Seki and Arai, 1991), rabbit anti-NeuN (1:1000, ab177487, Abcam). Immunohistochemistry of common marmoset brain sections was performed according to the method described in Cereb.Cortex.30, 4092-4109 (2020). More specifically, adult brains were perfusion-fixed with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) and further fixed in the same fixative overnight at 4°C. 60 μm-thick coronal and sagittal sections were prepared using a vibratome (VT-1200S, Leica) and incubated in blocking solution for 1 h at room temperature. These sections were incubated with primary antibodies in blocking solution overnight at 4°C, and then incubated with AlexaFluor488 / 647-labeled secondary antibodies (1:1,000, Invitrogen) in blocking solution for 3 h at room temperature.The primary antibodies used were guinea pig anti-Dcx (1:400, AB2253, Millipore; RRID:AB_1586992) and mouse IgM anti-PSA-NCAM (1:400).

[0036] Images were acquired by scanning at 2 μm intervals using a LSM 700 confocal laser scanning microscope (Carl Zeiss) equipped with a 20× objective. The fluorescence intensity of PSA-NCAM in Dcx+ cells (Dcx positive cells) was quantified using ZEN software (Carl Zeiss). Dcx positive cells or Dcx positive NeuN positive cells in the injured brain were counted in every sixth 50 μm coronal section. The total number per hemisphere was estimated by multiplying the sum by six.

[0037] (5) Real-time PCR To investigate the mRNA levels of Neu1 to Neu4 in normal and injured brains, the brains of wild-type mice were rapidly removed from the skull under deep anesthesia, either normal or 7 days after injury, and the cortex (Ctx), corpus callosum (CC), and striatum (St) were peeled off from the normal or injured brain. In the following explanation, the cortex and corpus callosum are collectively referred to as "Ctx, CC". Total RNA was extracted from the collected samples. An RNA extraction kit (CellAmp Direct RNA prep kit, Takara) was used for extraction. To investigate the mRNA levels of Neu1 to Neu4 in the cortex, corpus callosum, and striatum of normal brains or the cortex, corpus callosum, and striatum of injured brains, total RNA was extracted from the tissues using TRIzol reagent (Invitrogen). cDNA was synthesized using SuperScript IV Reverse Transcriptase (Invitrogen). Quantitative SYBR Green real-time PCR was performed using an ABI 7500 Fast Real-Time PCR device (Applied Biosystems) according to a known method (LS Zheng et al., 2015). The following primers were used for real-time PCR:Neu1 forward primer 5'-TGCCAGCCCTACGAGCTT-3' (SEQ ID NO: 1) and Neu1 reverse primer 5'-TGGTTCCGGCGTTGAT-3' (SEQ ID NO: 2) for amplifying a 52 bp Neu1 product, Neu2 forward primer 5'-CCCTGGCGTGTATCAGAA-3' (SEQ ID NO: 3) and Neu2 reverse primer 5'-AGCACAGCCGTGTGACATTAAC-3' (SEQ ID NO: 4) for amplifying a 61 bp Neu2 product, Neu3 forward primer 5'-GGCTGGACGGCTGGTA-3' (SEQ ID NO: 5) and Neu3 reverse primer 5'-TCGAAATCGGCTTGGTGTTC-3' (SEQ ID NO: 6) for amplifying a 60 bp Neu3 product, and Neu4 forward primer 5'-AAGGCACGTCCTTCCTACCA-3' (SEQ ID NO: 7) and Neu4 reverse primer 5'-AAGGCACGTCCTTCCTACCA-3' (SEQ ID NO: 8) for amplifying a 61 bp Neu4 product. The primers used were 5'-GCAACCACGAGCCGTCTCT-3' (SEQ ID NO: 8), GAPDH forward primer 5'-CATGGCCTTCCGTGTTCCTA-3' (SEQ ID NO: 9) and GAPDH reverse primer 5'-CACGTCAGATCCA-3' (SEQ ID NO: 10) to amplify a 55 bp GAPDH product as an endogenous control.

[0038] (6) Viral vectors and plasmids Neu1 knockdown plasmid and Neu4 knockdown plasmid were generated according to a known method (Ota et al., 2014). More specifically, the target sequences of mouse Neu1, Neu4, and LacZ (comparative example) genes were inserted into a modified Block-iT Pol II miR RNAi expression vector containing DsRed-express. The following pCSII lentivirus expression vectors were generated using the Gateway system (Invitrogen) (CSII-EF-DsRed-miR-Neu1, CSII-EF-DsRed-miR-Neu4, CSII-EF-DsRed-miR-LacZ miRNA). The knockdown (KD) efficiency of these vectors was evaluated by Western blotting. The sequences of the miRNAs used are as follows: miRNA insert for knocking down Neu1: TGCTGATAAGGAACACTATCCCTGTGGTTTTGGCCACTGACTGACCACAGGGAGTGTTCCTTAT (SEQ ID NO: 11), miRNA insert for knocking down Neu4: TGCTGTTCATAGGAAGTCCTGGTCCCGTTTTGGCCACTGACTGACGGGACCAGCTTCCTATGAA (SEQ ID NO: 12)

[0039] To generate lentiviral particles, the lentiviral vector and packaging vector (pCAG-HIVgp and pCMV-VSV-G-RSV-Rev) were transfected into HEK293T cells. Three days after transfection, the culture supernatant was concentrated by centrifugation at 8000 rpm and 4°C for 16 hours using an MX-307 microrefrigerated centrifuge (Tomy). 2 μL of the lentiviral suspension was stereotactically injected around the injury site (1.8, 1.6, 1.4, 1.2, 1.0, 0.8, 0.5 mm anterior, lambda lateral, 1.5-2.0 mm deep) in mice 7 days after brain injury (dpi).

[0040] (7) Co-culture of V-SVZ-derived newborn neurons with BV2 cells In vitro culture and time-lapse imaging of V-SVZ-derived newborn neurons were performed according to the method described in J. Neurosci.39, 9967-9988 (2019). More specifically, V-SVZ tissues from P0-P3 male and female wild-type mice were dissected and dissociated with trypsin-EDTA (Invitrogen). Cells were washed with L-15 medium (Invitrogen) containing 40 μg / ml DNase I (Roche Diagnostics) and transfected with the plasmid pCAGGS-EGFP using the Amaxa Nucleofector IV system (Lonza Walkersville). The transfected cells were collected in RPMI-1640 medium (Thermo Fisher Scientific) and reaggregated. These cell aggregates were placed on a monolayer of BV2 cells (provided by Dr. Takatoshi Ueki, Nagoya City University) embedded in 60% Matrigel (BD Biosciences), and cultured for 2 days in Neurobasal medium containing 2% NeuroBrew-21 (Invitrogen), 2 mM L-glutamine (Invitrogen), and 50 U / ml penicillin-streptomycin (Invitrogen), and time-lapse imaging was performed. Cells were treated with lipopolysaccharide (LPS; 100 ng / ml to 1 μg / ml) with or without neuraminidase inhibitors (DANA or Zanamivir; final concentration 1 mM) according to the method described in J. Biol. Chem. 290, 13202-14 (2015). Time-lapse imaging of randomly selected EGFP-expressing newborn neurons was performed using a fluorescence microscope (KEYENCE) and a 20x objective lens.

[0041] (8) EndoN treatment method and neuraminidase inhibitor administration method One microliter of PBS or EndoN (10 units / μl) was stereotactically injected into the lateral ventricle (-0.2 mm anterior, 0.6 mm lateral, 2.0 mm deep from bregma). For inhibition of neuraminidase, N-acetylglucosamine (DANA) (50 mg / kg), zanamivir (50 mg / kg), or PBS (control) was injected intraperitoneally daily from 7 to 21 dpi in mice and from 7 to 28 dpi in common marmosets.

[0042] (9) Quantitative Analysis of Sialic Acid Dissected mouse brain samples were homogenized in PBS containing 1% Triton X-100, protease inhibitor cocktail (1 μg / mL aprotinin, 1 μg / mL leupeptin, 1 μg / mL pepstatin, 2 μg / mL antipain), and 5 mM ethylenediaminetetraacetic acid (EDTA) and incubated on ice for 1 h. The homogenates were centrifuged, and the protein concentration of the supernatants was assessed by bicinchoninic acid (BCA) assay. Sialic acid (Sia) in each sample was quantified using the DMB derivatization method. More specifically, 1 μl of brain homogenate was hydrolyzed by incubation in 0.2 M trifluoroacetic acid (TFA) at 80 °C for 2 h. For DMB derivatization, 20 μl of 0.01 M TFA and 20 μl of DMB solution were added to the dried samples and incubated at 50 °C for 2 h. For fluorescence HPLC analysis, samples were diluted 10-fold and injected onto a Handy ODS column (250 × 4.6 mm id) (Wako) through a JASCO Intelligent Inert Sampler (AS-4050) and eluted with methanol / acetonitrile / water (7 / 9 / 84, v / v / v). The HPLC system consisted of a JASCO pump (PU-4180), a JASCO fluorescence detector (FP-2025 plus, excitation wavelength 373 nm, emission wavelength 448 nm), and a Chromato-PRO Integrator (Run Time Corporation).

[0043] 2. Experimental content and results <Experiment 1: Confirmation of morphology and cell adhesion of newborn neurons> The morphology and cell adhesion of the chains of newborn neurons in normal and injured brains were observed using SBF-SEM. The percentage of cell adhesion was quantified based on the results of SBF-SEM. Figure 4 is an explanatory diagram showing the image data of SBF-SEM in experiment 1. The upper side of the page in Figure 4 shows a normal brain (Normal), and the lower side shows an injured brain (Injury). The left side of the page in Figure 4 shows a chain of cells, and each cell is color-coded. The right side of the page in Figure 4 shows the state of cell adhesion, with the light gray area showing adhesion between newborn neurons and the dark gray area showing open extracellular space between neurons.

[0044] Newly generated neurons migrate within the brain while forming chains. As shown on the left side of the page in Figure 4, the chains in a normal brain have uniform cell orientation, and each newborn neuron has a smooth morphology. In contrast, the chains in the injured brain have non-uniform cell orientation, and the morphology of each newborn neuron is irregular.

[0045] Figure 5 is an explanatory diagram explaining the proportion of cell adhesion as a result of experiment 1. In Figure 5, similar to the right side of the page of Figure 4, the area where new neurons are attached to each other (New neurons) is shown in light gray, the gaps between neurons are shown in dark gray, and the area where new neurons are attached to other cells is shown in white. The vertical axis of Figure 5 shows the proportion of the area of ​​each area in percentage (%). As shown on the right side of the page of Figure 4 and in Figure 5, in the injured brain, the gaps between neurons were significantly smaller than in the normal brain, and the proportion of the area of ​​the area where new neurons are attached to each other was significantly larger. The gaps between neurons are known to be a characteristic of newborn neurons that migrate in groups. For this reason, it was suggested that the newborn neurons migrating in the injured brain have excessive cell adhesion compared to the normal brain, resulting in migration disorders.

[0046] <Experiment 2: Comparison of PSA signal intensity in newly generated neurons in normal and injured brains> Polysialic acid (PSA) is present on the surface of newborn neurons migrating in normal brains. PSA is also widely used as a marker for newborn neurons. However, details of PSA in newborn neurons migrating in injured brains have not been elucidated so far. Therefore, the inventors of the present application compared the PSA signal intensity of newborn neurons in normal and injured brains.

[0047] FIG. 6 is an explanatory diagram showing a microscope image in Experiment 2. The upper side of FIG. 6 shows a normal brain (Normal), and the lower side shows an injured brain (Injury). The left side of FIG. 6 shows the expression of Dcx, and the right side of FIG. 6 shows the expression of PSA-NCAM. Dcx is a marker for immature neurons, and PSA-NCAM is a polysialylated neural cell adhesion molecule. FIG. 7 is an explanatory diagram showing the fluorescence intensity of PSA-NCAM in Experiment 2. FIG. 7 shows the fluorescence intensity of PSA-NCAM in Dcx-positive cells.

[0048] The results shown in Figures 6 and 7 reveal the following. PSA expression was also observed in newborn neurons in the injured brain, but the signal intensity was significantly reduced compared to that in the normal brain. This result suggests that the reduction in PSA levels is involved in the excessive adhesion between migrating newborn neurons in the injured brain.

[0049] <Experiment 3: Confirmation of the effect of administration of PSA-degrading enzyme on interneuron adhesion> To investigate whether the presence of PSA affects the adhesion of newborn neurons, we administered endoneuraminidaseN (endoN), a PSA degrading enzyme, into normal brains to remove PSA from newborn neurons. Specifically, 1 μL of phosphate-buffered saline (PBS, control) or 1 μL of endoN (10 units / μL) was injected into the lateral ventricle of Dcx-GFP mice. After 3 days, the mice were fixed and observed by immunohistochemistry and SBF-SEM.

[0050] FIG. 8 is an explanatory diagram showing a microscope image in Experiment 3. The upper side of FIG. 8 shows a comparative example (Ctrl), and the lower side shows an endoN-administered group (EndoN). The left side of FIG. 8 shows the expression of Dcx, the center shows the expression of PSA-NCAM, and the right side shows an SBF-SEM image. In the SBF-SEM image, the light gray area shows the adhesion between newborn neurons, and the dark gray area shows the gap between neurons. FIG. 9 is an explanatory diagram explaining the rate of cell adhesion as a result of Experiment 3. In FIG. 9, like the right side of FIG. 4 and the right side of FIG. 8, the area where newborn neurons are adhered to each other is shown in light gray, the gap between neurons is shown in dark gray, and the area where they are adhered to other cells is shown in white. The vertical axis of FIG. 9 shows the percentage (%) of the area of ​​each area.

[0051] As shown in the center of Fig. 8, the PSA signal intensity was significantly reduced in the endoN-administered group compared to the control group. As shown in the right side of Fig. 8 and Fig. 9, three-dimensional observation of cell adhesion by SBF-SEM revealed that the ratio of interneuronal gaps was significantly reduced and the ratio of interneuronal adhesion was increased in the endoN-administered group. The results shown in Fig. 8 and Fig. 9 suggest that excessive cell adhesion is caused by the reduction of PSA in the injured brain.

[0052] <Experiment 4: Examination of the possibility that neuraminidase is involved in the decrease of PSA> We investigated whether neuraminidase (Neu), an enzyme that hydrolyzes sialic acid, is involved in the decrease in PSA in newly generated neurons migrating within the injured brain.Expression levels of Neu1-4 in the cerebral cortex (Ctx), corpus callosum (CC), and striatum (St) of normal and injured brains were quantified using real-time PCR.

[0053] Fig. 10 is an explanatory diagram showing the expression levels of Neu1 to 4 in normal and injured brains. In the graph of Fig. 10, the results in normal brains are shown in white, the results in injured brains are shown in black, and the expression levels in the cortex and corpus callosum are shown together. The vertical axis of Fig. 10 shows the relative expression level when the sum of the expression levels in the cortex and corpus callosum of normal brains is set to 1.

[0054] The results in Figure 10 reveal the following. In other words, it was confirmed that the expression levels of Neu1 in the striatum and Neu4 in all regions of the injured brain were elevated compared to the expression levels in the normal brain. In particular, the expression level of Neu4 was more than two-fold elevated in the injured brain compared to the normal brain.

[0055] Fig. 11 is an explanatory diagram showing a comparison of the expression levels of Neu1 to 4 in injured brains. The graph in Fig. 11 shows the expression levels in the cortex and corpus callosum together, and the vertical axis in Fig. 11 shows the relative expression level when the expression level of Neu3 in the striatum, which has the lowest expression level, is set to 1.

[0056] The results in Figure 11 reveal the following: The expression levels of Neu1 and Neu4 were high in the cortex, corpus callosum, and striatum. The results in Figures 10 and 11 suggest that Neu1 and Neu4 are primarily involved in the reduction of PSA in the injured brain.

[0057] <Experiment 5: Confirmation of the effect of suppressing the expression of Neu1 and Neu4> To investigate the effect of Neu1 and Neu4 on the PSA level and migration of newborn neurons in the injured brain, cells around the injury were infected with viruses expressing miNeu1 and miNeu4 to suppress gene expression. As a comparative example, a knockdown vector that knocks down the LacZ gene was used. The cells were infected with the virus 7 days after brain injury, and fixed 21 days after brain injury, and observed and analyzed by immunohistochemistry.

[0058] FIG. 12 is an explanatory diagram showing the brain injury site of a mouse in Experiment 5. FIG. 13 is an explanatory diagram showing a microscopic image in Experiment 5. The left side of FIG. 13 shows the control group, the center shows the Neu1 knockdown group, and the right side shows the Neu4 knockdown group. In addition, in the image on the upper side of the page, DsRed, Dcx, and PSA-NCAM are shown, the brain injury site is shown with a dashed line, and the newborn neurons that migrate to the injury site are shown with an arrow. In the image showing the expression of Dcx on the lower side of the page and the image showing the expression of PSA-NCAM, the area surrounded by a square frame in the image on the upper side of the page is enlarged. FIG. 14 is an explanatory diagram showing the signal intensity in Experiment 5. The left side of FIG. 14 shows the signal intensity of PSA-NCAM, and the right side of FIG. 14 shows the signal intensity of Dcx-positive cells localized at the brain injury site.

[0059] The results shown in Figures 13 and 14 reveal the following. In other words, the PSA signal intensity of newborn neurons moving toward the injured area was significantly increased in the Neu1 knockdown group and the Neu4 knockdown group compared to the control group. Furthermore, the number of newborn neurons migrating toward the injured area was significantly increased in the Neu1 knockdown group and the Neu4 knockdown group compared to the control group. These results suggest that suppression of Neu1 expression and Neu4 expression in the injured brain leads to the maintenance of PSA in newborn neurons and can promote the migration of newborn neurons to the injured area.

[0060] <Experiment 6: Confirmation of promotion of new neuron migration by administration of neuraminidase inhibitor> To inhibit neuraminidase in brain tissues over a wider area, the neuraminidase inhibitor N-Acetyl-2,3-didehydro-2-deoxyneuraminic Acid (DANA) or the anti-influenza drug zanamivir was administered intraperitoneally at 50 mg / kg for 14 consecutive days from 7 to 21 days after brain injury. PBS was administered intraperitoneally to the control group under the same conditions. After 21 days of brain injury, the brains were fixed and observed and analyzed by immunohistochemistry.

[0061] FIG. 15 is an explanatory diagram showing the microscopic images in Experiment 6. The left side of FIG. 15 shows the control group, the center shows the DANA-administered group, and the right side shows the zanamivir-administered group. The image on the upper side of the page shows a relatively wide area covering the corpus callosum, striatum, and ventricle, and the image on the lower side of the page shows representative examples of an image showing the expression of Dcx and an image showing the expression of PSA-NCAM. FIG. 16 is an explanatory diagram showing the signal intensity in Experiment 6. The left side of FIG. 16 shows the signal intensity of PSA-NCAM, and the right side of FIG. 16 shows the signal intensity of Dcx-positive cells surrounding the brain injury site.

[0062] The results shown in Figures 15 and 16 reveal the following. In other words, the PSA signal intensity of newborn neurons moving toward the injured site was significantly increased in the neuraminidase inhibitor-administered group compared to the control group. Furthermore, the number of newborn neurons migrating toward the injured site was significantly increased in the neuraminidase inhibitor-administered group compared to the control group. These results suggest that administration of a neuraminidase inhibitor promotes the maintenance of PSA in newborn neurons and their migration toward the injured site.

[0063] <Experiment 7: Confirmation of promotion of neuronal regeneration by administration of neuraminidase inhibitor> To investigate whether administration of a neuraminidase inhibitor contributes to neuronal regeneration, DANA was administered intraperitoneally at 50 mg / kg for 14 consecutive days from 7 to 21 days after brain injury. PBS was administered intraperitoneally to the control group under the same conditions. After fixation 35 days after brain injury, the mice were observed and analyzed by immunohistochemistry.

[0064] FIG. 17 is an explanatory diagram showing a microscopic image in Experiment 7. The left side of FIG. 17 shows the control group, and the right side shows the DANA-administered group. The image in the upper part of the page shows Dcx and NeuN, a marker for mature neurons. The image in the lower part showing the expression of Dcx and NeuN and the image showing only the expression of Dcx show an enlarged area surrounded by a square frame in the image in the upper part of the page. In FIG. 17, Dcx-positive NeuN-positive cells, i.e., double-positive cells of Dcx and NeuN, are indicated by arrows. FIG. 18 is an explanatory diagram showing the number of double-positive cells in Experiment 7. In FIG. 18, the number of double-positive cells located at a distance of 600 μm or less from the ventricular-subventricular zone (V-SVZ) and the number of double-positive cells located at a distance of more than 600 μm are shown, respectively.

[0065] The results shown in Figures 17 and 18 reveal the following. Specifically, it was revealed that the number of newborn neurons expressing NeuN around the injury area was significantly increased in the neuraminidase inhibitor-administered group compared to the control group. Furthermore, it was revealed that the number of double-positive cells distributed at a distance of 600 μm or more from the subventricular zone where newborn neurons are produced was significantly increased in the neuraminidase inhibitor-administered group compared to the control group. These results suggest that administration of a neuraminidase inhibitor promotes the migration of newborn neurons and allows the newborn neurons to reach the injury site and mature.

[0066] <Experiment 8: Confirmation of recovery of motor function by administration of neuraminidase inhibitor> We investigated whether administration of neuraminidase inhibitors contributes to the recovery of motor functions lost due to injury. Neuraminidase inhibitors DANA or zanamivir were administered intraperitoneally at 50mg / kg for 14 consecutive days from 7 days to 21 days after brain injury, when the migration of new neurons is assumed to begin. PBS was administered intraperitoneally under the same conditions to the control group. Foot Fault Test (FFT) was performed before brain injury, 7 days after brain injury, and 35 days after brain injury. Motor function was analyzed 35 days after brain injury, when the peak of migration of new neurons is assumed to have ended and new neurons begin to mature.

[0067] Figure 19 is an explanatory diagram showing the FFT. The FFT is one of the behavioral tests, and it evaluates the walking function by making the mouse walk on a net and comparing the frequency of the mouse limbs slipping off the net between the left and right sides. The FFT was performed with modifications to a known method (Hernandez et al., 1988). Specifically, the mouse was placed on an elevated wire hexagonal grid with a 40 mm wide opening and allowed to walk around freely. If the mouse slipped or fell because its limbs fell into the gaps of the grid, a misstep was recorded as a foot fault. The number of foot faults for each limb was counted for 10 minutes, and the ratio of the number of faults for the contralateral (left) forelimb and hindlimb to the total number of faults for the four limbs was calculated as a percentage.

[0068] FIG. 20 is an explanatory diagram showing the results of Experiment 8. The vertical axis of FIG. 20 indicates the rate at which the left hand and foot fell off the net. The results shown in FIG. 20 reveal the following. That is, the rate at which the left hand and foot fell off the net was about 50% in both the neuraminidase inhibitor-administered group and the control group before injury, and 7 days after injury, the rate increased in both groups compared to before injury. In contrast, 35 days after injury, the rate of left-side slippage was significantly lower in the neuraminidase inhibitor-administered group than in the control group. These results suggest that the recovery of motor functions lost due to cerebral infarction, etc., can be promoted by administering a neuraminidase inhibitor during the period when new neurons are actively migrating.

[0069] <Experiment 9: Quantitation of sialic acid in injured brain> As an additional experiment to experiment 6, the concentration of sialic acid (Neu5Ac) in the RMS (rostral migratory stream) of normal brain and in areas 1 and 2, which are different distances from the injury site, was quantitatively analyzed using HPLC (high performance liquid chromatography). The n numbers for the DANA-treated group and the zanamivir-treated group were 4, and the n number for the control group, which was administered PBS instead of the neuraminidase inhibitor, was 3. Tukey's test was used for multiple comparisons. Error bars indicate the mean ± standard error of the mean.

[0070] FIG. 21 is an explanatory diagram showing a schematic diagram of the brain regions used for the quantification of sialic acid in Experiment 9. FIG. 22 is an explanatory diagram showing the quantification results of sialic acid in Experiment 9. In FIG. 22, the left side of the page shows a comparison between RMS and the injured brain region, the center of the page shows a comparison of each group in region 1, and the right side of the page shows a comparison of each group in region 2. The results shown in FIG. 22 revealed the following. That is, the sialic acid concentration in the injured brain regions (regions 1 and 2) was significantly reduced compared with the sialic acid concentration in normal RMS. Furthermore, administration of a neuraminidase inhibitor increased sialic acid in both regions 1 and 2. These results revealed that while injury reduces PSA, administration of a neuraminidase inhibitor increases sialic acid in both injured regions.

[0071] <Experiment 10: Co-culture of V-SVZ-derived newborn neurons with BV2 cells> Figure 23 is an explanatory diagram showing an outline of experiment 10. To examine whether administration of a neuraminidase inhibitor promotes neuronal migration, we co-cultured newborn neuronal cells with the microglial cell line BV2 as an in vitro system mimicking an injured brain. It has been reported that the microglial cell line BV2 releases neuraminidase upon stimulation with LPS (J. Biol.Chem.290, 13202-14 (2015)). Therefore, we co-cultured the cells to examine the PSA signal intensity after the addition of LPS, and examined the migration speed of newborn neurons by time-lapse imaging. In the following explanation, "LPS-" indicates the control without LPS addition, and "LPS+" indicates the addition of LPS. In the analysis of PSA signal intensity, the n number for the control (LPS-) was 6, and the n numbers for PBS (LPS+), DANA (LPS+), and Zanamivir (LPS+) were all 10. In time-lapse imaging, the n number for the control (LPS-) was 8, and the n numbers for PBS (LPS+), DANA (LPS+), and Zanamivir (LPS+) were all 30. For multiple comparisons, the Mann-Whitney U test was used. Error bars indicate the mean ± standard error of the mean.

[0072] FIG. 24 is an explanatory diagram showing a representative example of a microscopic image in Experiment 10. The upper side of FIG. 24 is an image showing the expression of Dcx and PSA-NCAM, and the lower side is an image showing only the expression of PSA-NCAM. FIG. 25 is an explanatory diagram showing the PSA signal intensity in Experiment 10. From the results shown in FIG. 24 and FIG. 25, the following was found. That is, as can be seen from the comparison between the control (LPS-) and PBS (LPS+), the PSA signal decreases due to LPS stimulation, but the PSA signal intensity is maintained by adding DANA or Zanamivir as a neuraminidase inhibitor.

[0073] FIG. 26 is an explanatory diagram showing the results of time-lapse imaging in Experiment 10. In FIG. 26, the numbers on the upper side of each time-lapse image indicate how many minutes after the first imaging frame the image was taken. In addition, in FIG. 26, the position of the newborn neuron is indicated by an arrowhead. FIG. 27 is an explanatory diagram showing the migration speed of neurons in Experiment 10. From the results shown in FIG. 26 and FIG. 27, the following was found. That is, it was revealed that the migration speed of neurons is reduced by LPS stimulation, but the migration speed of neurons is restored by adding a neuraminidase inhibitor. From the above results, it was suggested that PSA in newborn neurons is maintained and neuronal migration is promoted by administering a neuraminidase inhibitor.

[0074] <Experiment 11: Confirmation of promotion of neuronal regeneration by administration of neuraminidase inhibitor> As an additional experiment to experiment 7, we conducted an experiment using neuraminidase inhibitors DANA and zanamivir. The neuraminidase inhibitors were administered intraperitoneally at 50 mg / kg for 14 days starting 7 days after brain injury, and the brains were fixed 35 days after brain injury and observed and analyzed by immunohistochemistry.

[0075] FIG. 28 is an explanatory diagram showing a representative example of a microscopic image in Experiment 11. The left side of FIG. 28 shows a control group, the center shows a DANA-administered group, and the right side shows a zanamivir-administered group. In addition, Dcx and NeuN are shown in the image on the upper side of the page. In the image showing the expression of Dcx and NeuN on the lower side of the page and the image showing only the expression of Dcx, the area surrounded by a square frame in the image on the upper side of the page is enlarged. In FIG. 28, the double-positive cells of Dcx and NeuN are indicated by arrows. Note that the double-positive cells of Dcx and NeuN show a mature morphology with long branched processes. FIG. 29 is an explanatory diagram showing the number of double-positive cells in Experiment 11. In FIG. 29, the number of double-positive cells located at a distance of 600 μm or less from the V-SVZ and the number of double-positive cells located at a distance of more than 600 μm are shown, respectively.

[0076] The results shown in Figures 28 and 29 reveal the following. That is, as in Experiment 7, the number of newborn neurons expressing NeuN around the injury was significantly increased in the neuraminidase inhibitor-administered group compared to the control group. Also, as in Experiment 7, the number of double-positive cells distributed at a distance of 600 μm or more from the V-SVZ was significantly increased in the neuraminidase inhibitor-administered group compared to the control group. The results of Experiment 11 also show that administration of a neuraminidase inhibitor promotes the migration of newborn neurons in the injured brain, allowing them to reach the injury site and mature.

[0077] <Experiment 12: Confirmation of whether recovery of motor function is due to neuronal regeneration> According to the above-mentioned experiment 8, the administration of neuraminidase inhibitors was confirmed to restore motor function. Therefore, to investigate whether the functional recovery observed in the inhibitor-administered animals was due to the regeneration of V-SVZ-derived neurons, we next used a system (Nestin-CreERT2; NSE-DTA) that specifically removes newly generated neurons. Nestin-CreERT2; NSE-DTA mice were injected with tamoxifen eight times starting 20 days before injury to express diphtheria toxin specifically in neurons, causing cell death. Then, brain injury was performed. Starting 7 days after injury, zanamivir was administered intraperitoneally at 50 mg / kg for 14 days, and 14 days after the end of zanamivir administration, behavioral tests (FFT) were performed and Dcx and NeuN double-positive cells were analyzed. NSE-DTA mice were used as a control. The n number for each group was 3, and t-test was used. Error bars indicate the mean ± standard error of the mean.

[0078] FIG. 30 is an explanatory diagram showing the results of Experiment 12. In FIG. 30, the left side of the page shows the number of double positive cells, and the right side of the page shows the results of FFT. As shown in FIG. 30, in the Nestin-CreERT2;NSE-DTA group, unlike the NSE-DTA group, the number of double positive cells for Dcx and NeuN was reduced even when a neuraminidase inhibitor was administered. Furthermore, in the Nestin-CreERT2;NSE-DTA group, unlike the NSE-DTA group, no improvement in the left side slippage rate in FFT was observed even with the administration of zanamivir. These results indicate that V-SVZ-derived neurons regenerated in the damaged brains of mice administered neuraminidase inhibitors contribute to functional recovery.

[0079] <Experiment 13: Confirmation of the effect of administration of neuraminidase inhibitors in primates> As a follow-up experiment to experiment 6, we confirmed whether the neuronal regeneration effect of administration of a neuraminidase inhibitor in the injured brain was observed in animal species more similar to humans. Common marmosets, a primate species, were given brain injury and zanamivir was administered intraperitoneally at 50 mg / kg for 21 days starting 7 days after injury. The brains were fixed and analyzed 28 days after brain injury. For immunostaining, the n number for the normal RMS group, the zanamivir-treated group, and the control group was 15, and the Mann-Whitney U test was used for multiple comparisons. For analysis of the migration distance of Dcx-positive cells from the injury site in the brain, the n number for the control group was 148 and the n number for the zanamivir-treated group was 140, and the Wilcoxon signed rank test was used for multiple comparisons. Note that error bars indicate the mean ± standard error of the mean.

[0080] FIG. 31 is an explanatory diagram showing a representative example of a microscopic image in Experiment 13. In FIG. 31, for each of the control group and the zanamivir-administered group, the upper left side of the page shows the expression of Dcx and the expression of PSA-NCAM, the lower left side of the page shows the expression of PSA-NCAM, the upper right side of the page shows a representative image of a common marmoset brain section stained with Dcx, and the lower right side of the page shows an enlarged area surrounded by a square frame in the image on the upper right side of the page. FIG. 32 is an explanatory diagram showing the signal intensity of PSA-NCAM in Experiment 13. In FIG. 32, the PSA-NCAM fluorescence intensity of Dcx-positive cells in normal RMS and the control group and zanamivir-administered group of injured brains is shown. FIG. 33 is an explanatory diagram showing the migration distance of Dcx-positive cells from the injury site in the brain.

[0081] From the results shown in Figures 31 to 33, the following was found. That is, in the control (zanamivir non-administration group), the PSA signal intensity of newborn neurons localized in the striatum on the injured side was reduced compared to the PSA signal intensity of newborn neurons localized in the RMS, but it was revealed that administration of zanamivir maintained the PSA signal intensity of newborn neurons localized in the striatum on the injured side. Furthermore, it was revealed that administration of zanamivir localized newborn neurons closer to the injured site. These results suggest that in primates as well as mice, administration of a neuraminidase inhibitor maintains PSA in newborn neurons migrating to the brain injury site, and promotes neuronal migration to the injury site. [Industrial Applicability]

[0082] According to the present invention, since the migration of neurons can be promoted, the number of neurons migrating to the injury site can be increased, and the effect of improving brain function by the nerve cells that reach the injury site and differentiate and mature can be expected. Therefore, for example, by administering to a patient with a brain disease such as cerebral infarction, it can be used to promote the migration of nerve cells produced from endogenous neural stem cells. In addition, for example, by administering to a patient who has undergone cell transplantation surgery, it can be used to promote the migration of transplanted nerve cells. In addition, for example, by combining with a technology such as biomaterials, it can be used to promote the migration and regeneration of nerve cells. In addition, for example, it can be administered to an experimental animal such as a brain disease model animal as a nerve cell migration promoter and used in research.

[0083] The present invention is not limited to the above-mentioned embodiment, and can be realized in various configurations without departing from the spirit of the present invention. For example, the technical features in the embodiments and examples corresponding to the technical features in each form described in the Summary of the Invention column can be appropriately replaced or combined in order to solve some or all of the above-mentioned problems or to achieve some or all of the above-mentioned effects. Furthermore, if a technical feature is not described as essential in this specification, it can be appropriately deleted.

Claims

1. A pharmaceutical composition for treating a brain disease, comprising: A pharmaceutical composition comprising a neuraminidase inhibitor.

2. 2. The pharmaceutical composition according to claim 1 , The neuraminidase inhibitor inhibits at least one of Neu1 and Neu4. Pharmaceutical compositions.

3. The pharmaceutical composition according to claim 1 or 2, Administration is started within 10 days after the onset of the brain disease and is administered daily. Pharmaceutical compositions.

4. 4. The pharmaceutical composition according to claim 3, Administered for 10 days or more, Pharmaceutical compositions.

5. The pharmaceutical composition according to claim 1 or 2, Administered in the form of an injectable drug, Pharmaceutical compositions.

6. A neuronal migration promoter, comprising a neuraminidase inhibitor.

7. The neuronal migration promoter according to claim 6, The neuraminidase inhibitor inhibits at least one of Neu1 and Neu4. A neuronal migration promoter.

8. A method for treating a brain disease, comprising: A method comprising the step of administering a neuraminidase inhibitor to a patient with a brain disease.

9. 1. A method for promoting neuronal migration, comprising: The method comprises the step of contacting said neuron with a neuraminidase inhibitor.

10. Use of neuraminidase inhibitors to treat brain diseases.

Citation Information

Patent Citations

  • Material for treating encephalopathy, method for treating encephalopathy, material for regenerating brain neuron, and method for regenerating brain neuron

    JP2020018796A

  • Vascular progenitor cell sheet derived from induced pluripotent stem cells, and production method therefor

    WO2013069661A1